Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Total Non-Current Liabilities (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Total Non-Current Liabilities for 16 consecutive years, with $62.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 3.03% to $62.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $62.5 million, a 3.03% decrease, with the full-year FY2024 number at $62.0 million, down 1.22% from a year prior.
  • Total Non-Current Liabilities was $62.5 million for Q3 2025 at Harvard Bioscience, down from $62.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $81.1 million in Q1 2022 to a low of $60.1 million in Q2 2024.
  • A 5-year average of $68.6 million and a median of $66.5 million in 2023 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: increased 13.73% in 2022, then dropped 14.07% in 2023.
  • Harvard Bioscience's Total Non-Current Liabilities stood at $78.5 million in 2021, then dropped by 8.06% to $72.1 million in 2022, then dropped by 12.92% to $62.8 million in 2023, then decreased by 1.22% to $62.0 million in 2024, then rose by 0.66% to $62.5 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Total Non-Current Liabilities are $62.5 million (Q3 2025), $62.9 million (Q2 2025), and $63.6 million (Q1 2025).